retatrutide latest clinical trial results New Phase 3 data just dropped π Eli Lilly's reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats The data just dropped β
Description
2019;27:S312
Koulen P, Malitschek B, Kuhn R, Bettler B, Wssle H, Brandsttter JH
If additional glycemic control is required, increase the dosage in 0.6 mg increments after at least one week on the current dosage
A representative community-reported taper from a 2 mg/week ceiling: Trial subjects in Phase 2 did not taper the trial extension was open-label continuation, not a structured taper
Cognitive benefits and Alzheimers research The protective effects of GLP-1 medications translate into meaningful cognitive improvements
Oh, and we've won quite a few awards along the way from across the industry and media
